Adverse events reporting in stage III NSCLC trials investigating surgery and radiotherapy

Thomas Iseli, Thierry Berghmans, Markus Glatzer, Achim Rittmeyer, Gilbert Massard, Valérie Durieux, Thomas Buchsbaum, Paul Martin Putora

Source: ERJ Open Res, 6 (3) 00010-2020; 10.1183/23120541.00010-2020
Journal Issue: July
Disease area: Thoracic oncology

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Thomas Iseli, Thierry Berghmans, Markus Glatzer, Achim Rittmeyer, Gilbert Massard, Valérie Durieux, Thomas Buchsbaum, Paul Martin Putora. Adverse events reporting in stage III NSCLC trials investigating surgery and radiotherapy. ERJ Open Res, 6 (3) 00010-2020; 10.1183/23120541.00010-2020

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Postoperative adjuvant treatment in stage III NSCLC
Source: Eur Respir J 2007; 30: Suppl. 51, 434s
Year: 2007

Resectability after two different chemotherapy regimens: results of the first step of a phase II randomised trial in initially resectable stage I – IIIa nonsmall cell lung cancer conducted by the European lung cancer working party
Source: Eur Respir J 2003; 22: Suppl. 45, 162s
Year: 2003

Is there any survival benefit of surgery after neoadjuvant chemoradiotherapy and persisting pn2/3 in stage III NSCLC?
Source: Annual Congress 2009 - Diagnosis and treatment of lung cancer
Year: 2009



Indcution chemotherapy and radiotherapy vs. induction and simultaneous radiochemotherapy in inoperable stage III NSCLC. Update on BROCAT study CTRT 99/97
Source: Eur Respir J 2006; 28: Suppl. 50, 833s
Year: 2006

A phase III randomised study comparing two different dose-intensity regimens as induction chemotherapy followed by thoracic irradiation in patients with advanced locoregional nonsmall cell lung cancer (NSCLC)
Source: Eur Respir J 2003; 22: Suppl. 45, 162s
Year: 2003

Definitive radiation therapy for elderly patients with stage III NSCLC not candidates for combined chemoradiation
Source: Annual Congress 2012 - Treatment of lung cancer
Year: 2012

Mode of early relapse in resectable I-IIIA NSCLC – prospective, controlled study
Source: Eur Respir J 2005; 26: Suppl. 49, 168s
Year: 2005

Phase II trial on neoadjuvant chemoradiation with paclitaxel/carboplatin in stage III NSCLC
Source: Annual Congress 2003 - Lung cancer staging and combined modality treatment
Year: 2003


SABRTooth: a randomised controlled feasibility study of stereotactic ablative radiotherapy (SABR) with surgery in patients with peripheral stage I nonsmall cell lung cancer considered to be at higher risk of complications from surgical resection
Source: Eur Respir J, 56 (5) 2000118; 10.1183/13993003.00118-2020
Year: 2020



The efficacy and safety of induction chemoradiotherapy (ICRT) followed by surgery in stage III NSCLC patients (pts) with T3/4-adjacent organ invasion involved(AOI): A single-center retrospective observational study.
Source: International Congress 2018 – Lung cancer: personalised medicine
Year: 2018



Stage IIIA/B NSCLC: long-term results of induction chemotherapy and surgery
Source: ISSN=ISSN 1810-6838, ISBN=, page=279
Year: 2008

The big lung trial (BLT): a major randomised trial examining the role of cisplatin-based chemotherapy in all stages of non-small cell lung cancer (NSCLC). Preliminary results in the supportive care setting
Source: Eur Respir J 2002; 20: Suppl. 38, 399s
Year: 2002

Clinical outcomes of stereotactic ablative body radiotherapy (SABR) in medically inoperable early stage lung cancer patients
Source: Virtual Congress 2021 – Therapy of lung cancer
Year: 2021


Improved results after preoperative concurrent chemotherapy and high dose radiation therapy in selected cases with stage III N2 lung cancer?
Source: Annual Congress 2012 - Treatment of lung cancer
Year: 2012

A randomised phase III trial by the European lung cancer working party comparing sequential administration of cisplatin-based chemotherapy followed by a taxan and a cisplatin-based standard chemotherapy, with the use of taxan as salvage treatment
Source: Eur Respir J 2006; 28: Suppl. 50, 833s
Year: 2006

Main reasons for a low accrual pattern in clinical trials of patients with advanced stage non-small cell lung cancer (NSCLC)
Source: Annual Congress 2008 - Influence of teaching models on skills and knowledge of medical doctors
Year: 2008


Modern radiotherapy as a curative treatment modality for stage III NSCLC
Source: International Congress 2019 – Locally advanced non-small cell lung cancer in 2019: novel diagnostic and therapeutic strategies to tackle complex stage III disease
Year: 2019


A phase III randomised trial assessing the activity of first-line ifosfamide-gemcitabine (IG), a non-platinum chemotherapy (CT), in patients with advanced non-small cell lung cancer (NSCLC)
Source: Annual Congress 2011 - Treatment of lung cancer
Year: 2011


Factors predicting complete surgical resection after induction chemotherapy in patients with initially unresectable non-small cell lung cancer (NSCLC) treated in a randomised trial
Source: Eur Respir J 2003; 22: Suppl. 45, 162s
Year: 2003